Philip D Greenberg
Overview
Explore the profile of Philip D Greenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
8316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie J, Chen D, Chour W, Ng R, Zhang R, Yuan D, et al.
Nat Commun
. 2025 Feb;
16(1):1402.
PMID: 39915487
Elucidating the relationships between a class I peptide antigen, a CD8 T cell receptor (TCR) specific to that antigen, and the T cell phenotype that emerges following antigen stimulation, remains...
2.
Xie J, Chen D, Chour W, Ng R, Zhang R, Yuan D, et al.
bioRxiv
. 2025 Jan;
PMID: 39829843
Elucidating the relationships between a class I peptide antigen, a CD8 T cell receptor (TCR) specific to that antigen, and the T cell phenotype that emerges following antigen stimulation, remains...
3.
Mazziotta F, Martin L, Eagan D, Bar M, Kinsella S, Paulson K, et al.
medRxiv
. 2025 Jan;
PMID: 39763516
Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk patients was...
4.
Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y, et al.
Cancer Cell
. 2024 Dec;
43(1):103-121.e8.
PMID: 39642888
Cellular metabolic status profoundly influences T cell differentiation, persistence, and anti-tumor efficacy. Our single-cell metabolic analyses of T cells reveal that diminished mannose metabolism is a prominent feature of T ...
5.
Gupta S, Martinov T, Thelen A, Sunahara M, Mureli S, Vazquez A, et al.
bioRxiv
. 2024 Nov;
PMID: 39574748
Background: Progressive multifocal leukoencephalopathy (PML) is a frequently fatal disease of the central nervous system caused by JC virus (JCV). Survival is dependent on early diagnosis and ability to re-establish...
6.
Lee J, Chen E, Hu T, Perret R, Chaffee M, Martinov T, et al.
bioRxiv
. 2024 Sep;
PMID: 39345486
One-sentence Summary: Tumor cell methylation of KRAS epitope in HLA-A2 permits immune evasion, and new TCRs were generated to overcome this with engineered cell therapy.
7.
Asano Y, Veatch J, McAfee M, Bakhtiari J, Lee B, Martin L, et al.
medRxiv
. 2024 Jul;
PMID: 39006423
Although immune check-point inhibitors (CPIs) revolutionized treatment of Merkel cell carcinoma (MCC), patients with CPI-refractory MCC lack effective therapy. More than 80% of MCC express T-antigens encoded by Merkel cell...
8.
Shasha C, Glass D, Moelhman E, Islas L, Tian Y, Szeto G, et al.
bioRxiv
. 2024 Jun;
PMID: 38895348
Dysregulation of the bone marrow (BM) niche in multiple myeloma (MM) alters the composition and state of resident immune cells, potentially impeding anti-tumor immunity. One common mechanism of immune inhibition...
9.
Krakow E, Brault M, Summers C, Cunningham T, Biernacki M, Black R, et al.
Blood
. 2024 Apr;
144(10):1069-1082.
PMID: 38683966
Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific...
10.
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy
Martinov T, Greenberg P
Annu Rev Cancer Biol
. 2023 Sep;
7(1):331-351.
PMID: 37655310
T cell reactivity to tumor-specific neoantigens can drive endogenous and therapeutically induced antitumor immunity. However, most tumor-specific neoantigens are unique to each patient (private) and targeting them requires personalized therapy....